Data / Drug companies / Lupin Pharmaceuticals,Inc.
Lupin Pharmaceuticals,Inc.: 92 products in the FDA NDC directory, labeler code 43386
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Lupin Pharmaceuticals,Inc. (labeler code 43386) lists 92 products in the FDA National Drug Code Directory, covering 40 finished drugs by generic name. By type: 90 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on January 29, 2024.
The request: Watch Lupin Pharmaceuticals,Inc. (FDA labeler code 43386): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 43386
- Products in commercial distribution
- 92
- Packages
- 120
- Finished drugs by generic name
- 40
- Prescription products
- 90
- Over the counter products
- 2
- Controlled substance products
- Schedule II 35, Schedule IV 5
- Flagged as original packager
- 92 of 92 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- June 19, 1998
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 92 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 90 | 97.8% |
| Over the counter drugs | 2 | 2.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 45 | 48.9% |
| Solution | 10 | 10.9% |
| Capsule | 9 | 9.8% |
| Tablet, film coated, extended release | 5 | 5.4% |
| Powder, for solution | 4 | 4.3% |
| Tablet, chewable | 3 | 3.3% |
| Tablet, extended release | 3 | 3.3% |
| Tablet, orally disintegrating | 2 | 2.2% |
| Tablet, film coated | 2 | 2.2% |
| Gel | 2 | 2.2% |
| Spray, metered | 1 | 1.1% |
| Suspension | 1 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Cyanocobalamin | 43386-237 | Spray, metered | Generic drugs (ANDA) | January 29, 2024 |
| Diazepam | 43386-281 | Gel | Generic drugs (ANDA) | October 30, 2023 |
| Diazepam | 43386-280 | Gel | Generic drugs (ANDA) | October 30, 2023 |
| Sodium sulfate, potassium sulfate, magnesium sulfate | 43386-700 | Solution | Generic drugs (ANDA) | December 30, 2022 |
| Potassium Chloride | 43386-194 | For solution | Generic drugs (ANDA) | November 21, 2018 |
| Potassium chloride | 43386-169 | Solution | Generic drugs (ANDA) | September 24, 2018 |
| Potassium chloride | 43386-168 | Solution | Generic drugs (ANDA) | September 24, 2018 |
| Nitrofurantoin macrocrystals | 43386-642 | Capsule | Generic drugs (ANDA) | July 9, 2018 |
| Nitrofurantoin macrocrystals | 43386-641 | Capsule | Generic drugs (ANDA) | July 9, 2018 |
| Clobetasol propionate | 43386-096 | Ointment | Generic drugs (ANDA) | June 2, 2018 |
| Carbidopa | 43386-980 | Tablet | Generic drugs (ANDA) | October 20, 2017 |
| Doxycycline Hyclate | 43386-794 | Tablet | Generic drugs (ANDA) | September 6, 2017 |
| Fluocinonide | 43386-026 | Solution | Generic drugs (ANDA) | July 21, 2017 |
| Flucytosine | 43386-771 | Capsule | Generic drugs (ANDA) | July 7, 2017 |
| Flucytosine | 43386-770 | Capsule | Generic drugs (ANDA) | July 7, 2017 |
| Oxycodone Hydrochloride | 43386-434 | Tablet | Generic drugs (ANDA) | June 12, 2017 |
| Oxycodone Hydrochloride | 43386-433 | Tablet | Generic drugs (ANDA) | June 12, 2017 |
| Oxycodone Hydrochloride | 43386-432 | Tablet | Generic drugs (ANDA) | June 12, 2017 |
| Oxycodone Hydrochloride | 43386-431 | Tablet | Generic drugs (ANDA) | June 12, 2017 |
| Oxycodone Hydrochloride | 43386-430 | Tablet | Generic drugs (ANDA) | June 12, 2017 |
| Oxycodone and Acetaminophen | 43386-493 | Tablet | Generic drugs (ANDA) | February 24, 2017 |
| Oxycodone and Acetaminophen | 43386-492 | Tablet | Generic drugs (ANDA) | February 24, 2017 |
| Oxycodone and Acetaminophen | 43386-491 | Tablet | Generic drugs (ANDA) | February 24, 2017 |
| Oxycodone and Acetaminophen | 43386-490 | Tablet | Generic drugs (ANDA) | February 24, 2017 |
| Cevimeline hydrochloride | 43386-999 | Capsule | Generic drugs (ANDA) | December 30, 2016 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.